摘要:目的:探讨马来酸曲美布丁联合布拉氏酵母菌治疗腹泻型肠易激惹综合征的临床疗效及安全性。方法收集2010年6月~2013年8月期间在本院消化科就诊的DIBS患者114例,随机分为联合组和对照组,每组67例。对照组采用马来酸曲美布丁治疗,联合组在对照组基础上加用布拉氏酵母菌治疗,比较两组腹泻、腹痛症状评分及临床症状总积分,同时观察临床疗效及不良反应发生情况。结果联合组显效率、总有效率分别为52.2%、91.0%,对照组分别为34.3%、74.6%,联合组显效率、总有效率明显高于对照组( P<0.05)。联合组治疗后腹痛、腹泻评分及临床症状总积分分别为(1.8±0.2)分、(1.8±0.2)分、(3.6±0.5)分,对照组(1.5±0.3)分、(1.3±0.2)分、(2.8±0.3)分,联合组治疗后腹痛、腹泻评分及临床症状总积分明显高于对照组(P<0.05)。联合组、对照组不良反应发生率分别为13.4%、14.9%,两组不良反应发生率无明显差异(P>0.05)。结论马来酸曲美布丁联合布拉氏酵母菌治疗DIBS具有协同增效作用,能更有效的改善患者的临床症状,提高临床疗效,且安全可靠,值得临床推广应用。%Objective To investigate the clinical effect and safety of treating diarrhea irritable bowel syndrome(DIBS) by trimebutine maleate and saccharomyces boulardii.Methods 114 patients with DIBS who were treated in digestive department of our hospital from Jun, 2010 to Aug,2013, They were randomly divided into combination group and control group. There were 67 patients in each group. Control group were treated by trimebutine maleate, combination group were treated saccharomyces boulardii on basic of control group,the symptoms score of diarrhea, abdominal pain symptoms, and total clinical symptom integral were compared between two group.At the same time, the clinical effect and adverse reaction were observed.Results The excellence rate and total effective rate in combination group were respectively 52.2%, 91.0%, those in control group were respectively 34.3%, 74.6%, the excellence rate and total effective rate in combination group were obviously higher than those in control group (P<0.05), the symptoms score of diarrhea, abdominal pain and total clinical symptom integral in combination group were respectively (1.8±0.2) score, (1.8±0.2)score, (3.6±0.5) score after treatment.those in control group were respectively(1.5±0.3) score,(1.3±0.2) score,(2.8±0.3)score. The symptoms score of diarrhea, abdominal pain and total clinical symptom integral of combination group were obviously higher than those in control group(P<0.05).The incidence of adverse reaction in combination group and control group were respectively 13.4%, 14.9%, the incidence of adverse reaction between two groups had no significant difference (P>0.05).ConclusionThere are synergistic effect in treating DIBS by trimebutine maleate and saccharomyces boulardii. It can more effectively improve patient's clinical symptoms, improve clinical efficacy and it is safe and reliable,so it is well worthy of popularizing.